CHAPEL HILL, N.C., June 03, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the recent opening of study A5413, a study that expands upon the network’s commitment to finding a cure for HIV by looking at the HIV reservoir in people living with HIV who are on antiretroviral therapy (ART). A5413 is a randomized, double-blind, placebo-controlled clinical trial evaluating the safety, tolerability, and impact on the HIV reservoir of oral dasatinib among people living with HIV whose viral load is controlled by taking ART.